JP2006514636A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514636A5
JP2006514636A5 JP2004557434A JP2004557434A JP2006514636A5 JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5 JP 2004557434 A JP2004557434 A JP 2004557434A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5
Authority
JP
Japan
Prior art keywords
composition
wta
infection
antibody
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038132 external-priority patent/WO2004050846A2/en
Publication of JP2006514636A publication Critical patent/JP2006514636A/ja
Publication of JP2006514636A5 publication Critical patent/JP2006514636A5/ja
Pending legal-status Critical Current

Links

JP2004557434A 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Pending JP2006514636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Publications (2)

Publication Number Publication Date
JP2006514636A JP2006514636A (ja) 2006-05-11
JP2006514636A5 true JP2006514636A5 (enExample) 2007-06-07

Family

ID=32469426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557434A Pending JP2006514636A (ja) 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸

Country Status (6)

Country Link
US (1) US20040247605A1 (enExample)
EP (1) EP1567868A4 (enExample)
JP (1) JP2006514636A (enExample)
AU (2) AU2003298770A1 (enExample)
CA (1) CA2507711A1 (enExample)
WO (1) WO2004050846A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
WO2007024852A2 (en) * 2005-08-22 2007-03-01 Biosynexus Incorporated Methods for testing vaccine candidates against bacterial infection in rodents
WO2007047189A2 (en) * 2005-10-11 2007-04-26 Iogenetics, Llc Targeted biocides
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009151561A2 (en) * 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Wta를 유효성분으로 함유하는 백신 조성물
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
US20150147328A1 (en) * 2012-05-07 2015-05-28 Mogam Biotechnology Institute Vaccine composition for preventing staphyllococcus aureus infection
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
BR112015029838A2 (pt) * 2013-05-31 2017-09-26 Genentech Inc anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US20140356375A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
EP3150217A1 (en) * 2014-05-29 2017-04-05 Green Cross Corporation Composition for preventing or treating staphylococcus aureus infection
CN107206102A (zh) * 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2017198731A1 (en) * 2016-05-18 2017-11-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
US5904925A (en) * 1993-12-09 1999-05-18 Exner; Heinrich Adjuvant for antigens, and process for making
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
ATE219146T1 (de) * 1995-01-30 2002-06-15 Lunamed Ag Antitumorpräparate, die eine lipoteichonsäure aus streptococcus enthalten
WO1997013845A2 (en) * 1995-10-13 1997-04-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
JP2001510805A (ja) * 1997-07-23 2001-08-07 アンビィー インコーポレイテッド リソスタフィン単独含有もしくは抗生物質併用ブドウ球菌感染症治療用薬剤組成物
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
SI1141308T1 (sl) * 1998-12-22 2007-08-31 Microscience Ltd Streptokokni proteini skupine B in njihova uporaba
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CA2369762A1 (en) * 1999-04-16 2000-10-26 Peter P. Lee A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
US20020051793A1 (en) * 2000-09-12 2002-05-02 Drabick Joseph J. Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2003203079B8 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
WO2004096992A2 (en) * 2003-04-25 2004-11-11 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Similar Documents

Publication Publication Date Title
JP2006514636A5 (enExample)
JP2022031635A5 (enExample)
JP2021063090A5 (enExample)
JP2019518742A5 (enExample)
JP2017512193A5 (enExample)
JP2007511593A5 (enExample)
JP2016507470A5 (enExample)
JP2015534579A5 (enExample)
CA2544920A1 (en) Method for the treatment of multiple sclerosis by inhibiting il-17 activity
JP2019031565A5 (enExample)
JP2013515079A5 (enExample)
JP2017514461A5 (enExample)
JP2012121878A5 (enExample)
JP2017507652A5 (enExample)
JP2007510639A5 (enExample)
JP2009511480A5 (enExample)
JP2015534578A5 (enExample)
JP2008538564A5 (enExample)
JP2014525933A5 (enExample)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
RU2016116949A (ru) Анти-лпс о11-антитело
JP2014524902A5 (enExample)
JP2017519768A5 (enExample)
JP2016513682A5 (enExample)
US20220041695A1 (en) Method for preventing or treating nosocomial pneumonia